.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Johnson and Johnson
US Department of Justice
Cipla
Daiichi Sankyo
US Army
Deloitte
Mallinckrodt
Chubb
Cantor Fitzgerald

Generated: December 16, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,877,933

« Back to Dashboard

Which drugs does patent 8,877,933 protect, and when does it expire?


Patent 8,877,933 protects NEXAVAR and is included in one NDA. There has been one Paragraph IV challenge on Nexavar.

This patent has thirty-seven patent family members in thirty-one countries.

Summary for Patent: 8,877,933

Title:Thermodynamically stable form of a tosylate salt
Abstract: The present invention relates to a novel form, thermodynamically stable at room temperature, of the tosylate salt of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}- -N-methylpyridine-2-carboxamide, to processes for its preparation, to medicaments comprising it and to its use in the control of disorders.
Inventor(s): Grunenberg; Alfons (Dormagen, DE), Lenz; Jana (Wuppertal, DE)
Assignee: Bayer Intellectual Property GmbH (Monheim, DE)
Application Number:11/664,363
Patent Claim Types:
see list of patent claims
Compound; Use; Composition; Process;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Bayer HlthcareNEXAVARsorafenib tosylateTABLET;ORAL021923-001Dec 20, 2005RXYesYes► Subscribe► SubscribeYYTREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA, ADVANCED RENAL CELL CARCINOMA, OR DIFFERENTIATED THYROID CARCINOMA.► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,877,933

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
04023130Sep 29, 2004
PCT Information
PCT FiledSeptember 20, 2005PCT Application Number:PCT/EP2005/010119
PCT Publication Date:April 06, 2006PCT Publication Number: WO2006/034797

International Patent Family for Patent: 8,877,933

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China101065360► Subscribe
Cuba20070068► Subscribe
Cyprus1113598► Subscribe
Denmark1797038► Subscribe
EcuadorSP077356► Subscribe
European Patent Office1797038► Subscribe
Israel181734► Subscribe
Spain2387812► Subscribe
Guatemala200500270► Subscribe
Hong Kong1114605► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
QuintilesIMS
Mallinckrodt
Argus Health
Dow
Boehringer Ingelheim
McKinsey
Moodys
AstraZeneca
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot